Neprilysin is a zinc-dependent endopeptidase. It is ubiquitous in distribution and promiscuous in function, with >50 putative peptide substrates with varying levels of in vitro and/or in vivo evidence of functional relevance. In the first part of this review, we discuss the genetic, structural, substrate, and pathophysiological aspects of neprilysin. We incorporate information provided by genetically modified models, as well as pre-clinical and clinical data from investigations of synthetic neprilysin inhibitors. We next highlight the value of neprilysin as a biotarget and weigh the clinical benefits of synthetic neprilysin inhibitors, either alone or in combination with antagonists of the renin-angiotensin system. Finally, we provide evidence about soluble neprilysin as a biomarker surrogate in patients with heart failure and identify important gaps that require further research before soluble neprilysin is used clinically. In sum, neprilysin is a versatile, veteran player returning yet again to center stage after an eventful career spanning >40 years. (J Am Coll Cardiol 2016;68:639-53) 
First discovered in 1973, NEP was identified as the only endopeptidase among 7 hydrolases found in the brush border of rabbit proximal renal tubule microvilli (2), a location facilitating metabolism of substrate peptides appearing in renal filtrate. Its activity was first quantified in vitro through investigation of its cleavage of insulin B-chain, which proved to be a good substrate. Within 1 year, Kerr and Kenny (3, 4) had demonstrated that the rabbit brush border enzyme was maximally active at neutral pH, could cleave glucagon, had an approximate molecular weight of 93 kDa, and was the first reported mammalian example of a zinc-activated endopeptidase. The renal enzyme was soon found to be identical to a brain endopeptidase, enkephalinase, which metabolizes endogenous opioids and for which inhibition has antinociceptive effects (5, 6) . NEP was also shown to be identical to a lymphocyte marker designated CALLA (CD10) (7, 8) . Subsequently, discoveries of the wide anatomic distribution of NEP and its bewilderingly extensive array of candidate substrates have and 2b share the same 5 0 sequence but have 2 distinct donor splice-sites 171 bp apart. The interspecies conservation of its 5 0 untranslated sequences and the existence of 5 0 alternative splicing are consistent with differential control of NEP expression during development and tissue-specific regulation (11) .
NEP is an integral type II, membrane-bound, zinc-dependent endopeptidase composed of 749 amino-acid residues (12) (13) (14) . Its ectodomain, a member of the M13 family of peptidases, comprises 2 alpha-helical structures forming a spherical, waterfilled cleft presenting the catalytic site. The larger of the 2 ectodomain portions is structurally related to the bacterial protease thermolysin. It contains a single zinc atom, essential for catalytic activity, which is coordinated by His and Glu residues. The enzyme also has a transmembrane domain and a short intracellular domain. NEP cleaves peptides with a molecular weight generally at or below 3,000 Da and cannot attack large proteins. This degree of size-related specificity is conferred by size-restricted access to the catalytic crypt ( Figure 1) (14) . NEP hydrolyzes peptides to the amino side of hydrophobic amino acids, with a predilection for Phe or Leu at the P1 position and preferential release of di-or tripeptides from the carboxy-terminus of substrates.
NEP is found in epithelia, fibroblasts, and neutrophils and in soluble form in the circulation, urine, and cerebrospinal fluid (CSF) (15) (16) (17) (18) (19) . After its original isolation from renal brush-border membranes, studies in several species, using NEP antibodies or labeled NEP inhibitors, have located NEP in the brain, heart, peripheral vasculature, adrenal gland, lungs, gastrointestinal secretory epithelial brush borders, thyroid, placental syncytiotrophoblasts, arthritic synovium, and the male genital tract (15, 16, 18, (20) (21) (22) .
The renal brush border has long been recognized as rich in membrane-bound NEP, and a soluble form of the enzyme also appears in urine (15, 16, 19) . In the circulation, NEP is a soluble circulating enzyme, and it is also present on the plasma membranes of neutrophils, where it may cleave the chemotactic peptide fMet-Leu-Phe and modulate the chemotactic response of neutrophils (16, 23) . Soluble neprilysin (sNEP) in blood, urine, and CSF retains catalytic activity, as demonstrated by assays of plasma NEP activity (17, 18) . The close similarities between membrane-bound NEP and sNEP with respect to affinity constants for various inhibitors, and optimal pH and Michaelis constant for test substrates, further suggest that sNEP plays a role in cleaving circulating substrates. However, measured maximal velocity values are much lower in CSF, plasma, and amniotic fluid, suggesting enzymatic activity is predominantly tissue based. The processes whereby NEP is solubilized to appear in these body fluids are unknown.
NEP is expressed in cardiac fibroblasts and cardiomyocytes, and it appears to be more important than angiotensin-converting enzyme (ACE) in clearance of cardiac bradykinin (24) . In contrast to ACE, which is enriched in endothelial cells, vascular NEP is more of a fibroblast product (15, 16) . In lung, membrane-bound NEP appears within airways in cells that are associated with tachykinin receptors. NEP is present in the basal cells of airway epithelium, nerves, smooth muscle, glands, and blood vessels. It is also enriched in the pulmonary interstitium and alveolar cells (16, (25) (26) (27) . In the brain, the distribution of NEP maps with opioid receptors in structures related to pain control and in the caudate-putamen, globus pallidus, and substantia nigra. In the latter 2 structures, NEP is associated with presynaptic axonal terminals well placed to metabolize neurotransmitters. It is abundant on epithelial surfaces in contact with the CSF, including choroid plexus, pial membranes, and ependymal cells (15, 16, 28) . NEP is also present in the Schwann cells of many peripheral nerves (15).
In the gut, the jejunal brush-border epithelium is particularly enriched in NEP (29, 30 
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The exact relationship of these findings to in vivo clearance of human BNP is unclear (34) .
Initial and secondary NEP cleavage sites on NP are shown in Figure 3 . In health, proteolytic cleavage and removal by the "clearance" NP receptor, NPR-C, play equal roles in metabolism of the NPs, but in high NP states, such as HF, it seems likely that NEP plays an increasingly important role (34) . bioavailability of these agents has been well reviewed and cannot be detailed here (16) . Clearly, relative affinity for NEP, achieved circulating concentrations, and the spectrum of tissue penetration by specific inhibitors (to variably access the wide array of NEP substrates), will influence the net impact of any single NEP inhibitor. Thiorphan, the first synthetic NEPi, was followed by many other agents suitable for both oral and parenteral administration; these agents have been tested in animals (42, 44, 45) and humans in health and disease (16, (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) . Bayes-Genis et al.
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A U G U S T 9 , 2 0 1 6 : 6 3 9 - to enalapril with respect to the primary endpoint of death from any cause or admission for HF (71) .
Notably Neprilysin is a highly versatile enzyme, again in the spotlight, after an eventful career of >40 years. For decades, neprilysin has been an important biotarget. Neprilysin inhibitor (NEPi) monotherapy failed due to lack of efficacy, and NEPi þ angiotensin-converting enzyme (ACE) inhibition was abandoned due to lack of safety.
Recent development of angiotensin receptor-neprilysin inhibitor (ARNi) has shown robust evidence of safety and short-term to mid-term efficacy in patients with heart failure with reduced ejection fraction (HFrEF). The value of neprilysin as a biomarker (soluble neprilysin [sNEP]) is more recent, and it has been explored in 3 settings:
HFrEF, HF with preserved ejection fraction (HFpEF), and acutely decompensated heart failure (ADHF). Preanalytical and analytical gaps must be addressed before its translation from research-only to the clinic. 
A U G U S T 9 , 2 0 1 6 : 6 3 9 -5 3 amyloid-beta content of the brain is increased, and amyloid plaques appear along with neurofibrillary tangles. Introduction of an NEPi into mouse brain or a genetic deletion of NEP in mice that are usually also transgenic for an amyloid precursor protein variant generally replicates these findings, in association with indicators of impaired cognitive function (77) (78) (79) . Introduction of the NEP gene using a lentivirus vector has been reported to rescue this progression (80) . However, reports are not unanimous, (84) . In view of the likely prolonged use of NEPIs in the context of combination ARB/NEPi agents in HF, clarification of the clinical relevance of this wellfounded theoretical concern is mandatory. Table 1) . This raises the possibility of NEPis triggering unintended and potentially adverse effects in these systems.
In the lung, NEP's location near neurokinin receptors allows cleavage of tachykinins (exemplified by substance P) (25, 26) . NEP inactivates tachykinins released from pulmonary sensory nerves, thus limiting neurogenic inflammation and diminishing smooth muscle contraction, bronchiolar secretion, neutrophil adhesion, and vascular permeability in experimental models of lung injury and inflammation (25, 27) . Epithelial injury from respiratory viral infections and exposure to irritants (e.g., cigarette smoke, toluene diisocyanate) reduces NEP levels (25) . NEP may eventually emerge as a novel biomarker (94) . However, the various assays currently used to measure NEP levels require further refinement and Moreover, improperly performed venipuncture may contribute to cellular lysis, releasing not only internal proteins but also parts of membrane-bound elements.
Thus, although measurements with the clinically approved diagnostic kits yield similar analytic recoveries in serum and plasma, in the case of sNEP, information is scarce.
If pre-analytic considerations are complex, the analytic process of measuring sNEP is simply puzzling. The lack of reference materials and reference measurement procedures seems logical at this early stage of scientific interest, but data comparisons using the different commercially available immunoassays reveal an alarming lack of transferability ( Figure 5 ). This scenario cannot be explained by 1 single factor but rather by an accumulation of many.
Immunogen sequence, antibody clonality, and calibrator choice are not well detailed by the manufacturers, as shown in Table 3 . These may be key issues, in addition to different dilution patterns and recommended assay temperatures.
As previously described in the present review, NEP belongs to the family of zinc-dependent metallopeptidases. These include the endothelinconverting enzymes 1 and 2, the Kell blood group protein, and the PEX gene product (97) . Because most of these proteins have structural similarities to NEP, cross-reactivity studies are indeed a major issue.
Moreover, the amino-acid sequences of the membrane metalloendopeptidase-like proteins MMEL and NEP2 are also highly homologous with NEP. NEP2 has 2 alternatively spliced forms: a membrane-bound and a soluble-secreted variant. The latter, also known as soluble secreted endopeptidase (98) , might be an interesting biomarker itself, but it can also be a highly confusing factor for sNEP analyses.
The ideal biomarker assay should be identified by a combination of 2 monoclonal antibodies specific to a well-defined region of sNEP, with null crossreactivity with the aforementioned similar molecules. Unfortunately, these requirements are not fulfilled by any of the marketed immunoassays. So which assay should we choose? According to data found in published reports, an effective limit of quantification of at least 0.250 mg/ml seems a minimum requirement for sNEP studies, as this limit has an intraseries coefficient of variation of <10% and an interseries coefficient of variation of <15% along the measurement range. Performance characteristics of the 4 commercially available assays fulfilling these characteristics are listed in Table 3 . The assay from Aviscera Bioscience (Santa Clara, California) may, at present, be preferred because of its adequate cross-reactivity studies, although it uses polyclonal antibodies.
The pioneering studies that investigated sNEP in clinical HF cohorts used a modified Aviscera sandwich immunoassay. Serum was chosen to minimize pre-analytic issues and matrix complexity. To improve analytic sensitivity and to obtain a lower limit of sample quantification, several modifications were made to incubation time, assay temperature, mixing intensity, and dilution pattern. Of note, after our publication, Aviscera Bioscience made modifications to the recommended procedures, including the recommended dilution patterns. Unfortunately, we recently detected a relevant analytic issue with a new large lot from Aviscera Bioscience (number 20112126), which displayed very poor sensitivity, despite calibration curves similar to those of previous lots. Such inconsistency is a major problem with polyclonal antibody-based assays, and it is not easy to avoid. We also explored the 
